1
|
Iyengar NM, Smyth L, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Dickler MN, Fornier MN, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Argolo D, Jack K, Ulaner G, Jochelson M, Baselga J, Norton L, Hudis CA, Dang CT. Abstract P4-21-34: Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The combination of taxanes with trastuzumab (H) and pertuzumab (P) for first line treatment of HER2-positive metastatic breast cancer (MBC) is associated with improved progression-free survival (PFS) and overall survival (OS). Treatment per physician's choice with anti-HER2 therapy after second line therapy is associated with a median PFS of 3 months. While continued use of H in therapeutic combinations after progression on H-based therapy is common, the efficacy of continuing HP-based treatment after progression on P-based therapy is unknown.
Methods: This is a single arm phase II trial of gemcitabine (G) with HP. Eligible patients had HER2-positive (IHC 3+ or FISH ≥ 2.0) MBC with prior HP-based treatment and ≤ 3 prior chemotherapies. Patients received G (1200 mg/m2) on days 1 and 8 of a q 3 week (w) cycle, and H (8 mg/kg load → 6 mg/kg) and P (840 mg load → 420 mg) q3w. The primary endpoint is PFS at 3 months. Secondary endpoints include OS, safety and tolerability. An exploratory endpoint is to compare PFS by RECIST criteria versus 18-F FDG-PET response criteria. Using a Simon optimal 2-stage design, 21 patients were enrolled in stage 1. The successful 3-month PFS rate for stage 1 was set at 57% to allow accrual to stage 2 for a total of 45 patients. The study therapy will be considered successful if at least 27/45 (60%) patients are progression free at 3 months.
Results: As of June 9, 2016, 28 patients are enrolled; 21 are evaluable at 3 months and 7 have not had 3-month evaluation. At 3 months, 16/21 (76%) are progression free; 5 patients have progressed. The 3 month-PFS results for evaluable patients will be updated. There are no cardiac or febrile neutropenic events to date. Initially, 5 of 22 (23%) patients required G dose reduction (4 due to grade 3 neutropenia and 1 due to grade 3 vomiting) and the study was amended to lower initial G dose to 1000 mg/m2.
Conclusions: The preliminary 3 month-PFS is 76% (95% CI 55% to 89%) in evaluable patients, and updated data will be presented. These findings suggest clinical benefit when P is continued beyond progression.
Citation Format: Iyengar NM, Smyth L, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Dickler MN, Fornier MN, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Argolo D, Jack K, Ulaner G, Jochelson M, Baselga J, Norton L, Hudis CA, Dang CT. Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-34.
Collapse
Affiliation(s)
- NM Iyengar
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - L Smyth
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - D Lake
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - A Gucalp
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - JC Singh
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - TA Traina
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - P DeFusco
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - MN Dickler
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - MN Fornier
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - S Goldfarb
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - K Jhaveri
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - S Modi
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - D Argolo
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - K Jack
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - G Ulaner
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - M Jochelson
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - L Norton
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - CA Hudis
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - CT Dang
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
2
|
Cadoo KA, Morris PG, Lake DE, D'Andrea GM, Dickler MN, Gilewski TA, Dang CT, McArthur HL, Bromberg JF, Goldfarb SB, Modi S, Robson ME, Seidman AD, Sklarin NT, Norton L, Hudis CA, Fornier MN. Abstract P2-16-12: An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-16-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The role of dasatinib, an oral SRC inhibitor is being explored for the treatment of metastatic breast cancer. In a phase I study, we previously established that the combination of dasatinib and weekly paclitaxel was feasible. The activity of this combination is currently being explored in an ongoing phase II trial. Since Src kinase has a major role in osteoclast function and dasatinib has established anabolic and anti-resorptive effects in bone in vitro, we hypothesized that patients receiving this combination would have good control of osseous metastases and primarily develop progression of disease in sites other than bone.
Patients and methods: Patients were included in this analysis if they participated in the phase I or II metastatic breast cancer studies and received dasatinib at or above the recommended phase II dose of 120mg with paclitaxel (80mg/m2 day 1 and 8 of each 21day cycle). Patients who discontinued therapy for reasons other than progression were excluded. Per protocol, patients were required to discontinue bisphosphonates or other bone modulating agents for the first 8 weeks of study due to the potential for hypocalcaemia. Thereafter, they were permitted to receive these agents at the discretion of their treating physician. Patients provided serum samples for correlative studies. Assessment of N-telopeptide of type 1 collagen (NTX), a product of mature bone collagen that reflects bone specific resorption, is planned.
Results: The median age of the 24 patients who met criteria for analysis was 50y (37 - 66y). Of these, 15 (63%) had ER+ disease, and 24 (100%) were negative for human epidermal growth factor receptor (HER2). At study entry, 17 (71%) patients had bone involvement. Following the initial eight week moratorium, 7 (29%) patients received a bisphosphonate or rank ligand inhibitor during treatment with dasatinib + paclitaxel. Patients received a median 2 months (range 1-23) of dasatinib + paclitaxel therapy. To date, 3 (13%) continue on therapy, and 21 (88%) have had progression of disease. Among patients who progressed, 18 (86%) have progressed in visceral sites and only 3 (14%) progressed in bone. Analyses of serum NTX levels are ongoing and will be compared by site of progression.
Conclusion: The potential role of serum NTX as a predictive biomarker of benefit from dasatinib and paclitaxel is being explored and updated results will be presented.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-12.
Collapse
Affiliation(s)
- KA Cadoo
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - PG Morris
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - DE Lake
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - GM D'Andrea
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - MN Dickler
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - TA Gilewski
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - CT Dang
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - HL McArthur
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - JF Bromberg
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - SB Goldfarb
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - S Modi
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - ME Robson
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - AD Seidman
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - NT Sklarin
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - L Norton
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - CA Hudis
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - MN Fornier
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
3
|
Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging 2013; 57:312-321. [PMID: 24322788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Breast cancer is comprised of a number of complex and heterogeneous subtypes with differing clinical behavior and outcomes. In recent years, significant advances have been made in discerning the molecular drivers of this disease, and characterizing distinct subtypes of breast cancer based on gene expression profiles. These advances have begun to translate into greater individualization of treatment for patients. Although these advances have shaped our understanding of the underlying biology of breast cancer, most clinical decisions are currently based on tumor expression of the estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). These biomarkers have prognostic and predictive significance in breast cancer and have important implications for tumor growth and metastatic patterns. In this review, we focus on the three broad phenotypes of breast cancer used in clinical practice; ER/PR positive, HER2 positive and triple negative breast cancer (TNBC), which is characterized by lack of expression of ER, PR and HER2. We discuss the influence of these tumor-related factors as well as histological subtype, on the potential for breast cancer recurrence and patterns of disease spread.
Collapse
Affiliation(s)
- K A Cadoo
- The Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, USA -
| | | | | |
Collapse
|
4
|
Morris PG, Lake D, McArthur HL, Gilewski T, Dang C, Chaim J, Patl S, Lim K, Norton L, Hudis CA, Fornier MN. Abstract P5-20-07: Phase II Trial of Dasatinib in Combination With Weekly Paclitaxel for Patients with Metastatic Breast Carcinoma. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-20-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Src kinase plays an important role in proliferation, survival, angiogenesis and metastasis in several malignancies including breast cancer. Therefore, inhibition of Src and other tyrosine kinases (TKs) represents a novel therapeutic approach. Dasatinib is a potent inhibitor of 5 oncogenic TKs, inhibits VEGF-stimulated proliferation, has potent bone anti-resorptive activity and selectively inhibits basal-type breast cancer growth. Preclinically, the combination of dasatinib and paclitaxel had superior antitumor activity to either agent alone. In a previous phase I study, we determined that, in combination with weekly paclitaxel, the optimum dose of dasatinib was 120mg. Of note, 4/9 (44%) patients treated at or above this dasatinib dose level had objective tumor response. We now present results from the phase II trial of this combination.
Methods: Patients with MBC, ECOG PS 0–1, normal hepatic, renal, marrow function were eligible. Patients had measurable, HER2-negative metastatic breast cancer (MBC), ≤2 prior therapies for MBC. Treatment consisted of weekly paclitaxel 80 mg/m2 IV 3/4 weeks + Dasatinib 120mg orally daily. Response was assessed by RECIST after every 8 weeks of therapy. Simon's two-stage optimal design was used to test the null hypothesis of a 15% response rate (RR) against the alternative of a 30% RR. In stage I, planned enrollment was 23 patients based on Type I and Type II errors of 10%. If 4 or more responses are observed, enrollment will be extended to 55 patients. Exploratory correlative biomarkers of clinical benefit include Src phosphorylation (p-Src) in peripheral blood mononuclear cells, plasma levels of VEGFR2 and collagen Type IV, circulating tumor cells (CTCs) and tumor gene expression profiling.
Results: 21 patients (19 females, 2 male) have enrolled; median age 48 (range 30–79). Patients received a median of 1 prior therapy for MBC (range 0–2). 6 patients are not assessable for response: 1 has received <8 weeks treatment, 5 came off study for toxicity (2 hypersensitivity reaction to paclitaxel, 1 infection, 1 diarrhea/nausea, 1 bleeding likely related to anticoagulation). Among the 15 patients assessable for response, best response to date is as follows: 2 (13%) patients partial response, 11 (73%) patients stable disease (SD) and 2 (13%) patients progression of disease. Of patients with SD, 6/11 (55%) continue on treatment after median of 2 months (range 2–10) and 5/11 (45%) patients have come off study after median of 10 months (range 3–21). Most toxicities have been hematological and low grade. Diarrhea and neuropathy have generally been low grade and no new toxicities related to the combination have occurred since expansion into the phase II. Potential biomarkers of clinical benefit including, p-Src, VEGFR2, collagen Type IV, and CTCs will be presented.
Conclusion: Data from this phase II has demonstrated preliminary evidence of activity for weekly paclitaxel and dasatinib 120mg in patients with MBC. These findings are consistent with data from this dose level in the earlier phase I study. Predictive biomarkers of clinical benefit are under investigation.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-20-07.
Collapse
Affiliation(s)
- PG Morris
- Memorial Sloan-Kettering Cancer Center, New York
| | - D Lake
- Memorial Sloan-Kettering Cancer Center, New York
| | - HL McArthur
- Memorial Sloan-Kettering Cancer Center, New York
| | - T Gilewski
- Memorial Sloan-Kettering Cancer Center, New York
| | - C Dang
- Memorial Sloan-Kettering Cancer Center, New York
| | - J Chaim
- Memorial Sloan-Kettering Cancer Center, New York
| | - S Patl
- Memorial Sloan-Kettering Cancer Center, New York
| | - K Lim
- Memorial Sloan-Kettering Cancer Center, New York
| | - L Norton
- Memorial Sloan-Kettering Cancer Center, New York
| | - CA Hudis
- Memorial Sloan-Kettering Cancer Center, New York
| | - MN Fornier
- Memorial Sloan-Kettering Cancer Center, New York
| |
Collapse
|
5
|
Gucalp A, Comen E, Redana S, Evangelista L, Giri DD, Zhang XH, Patil S, Akram M, Norton L, Hudis CA, Fornier MN. P4-16-06: Expression Patterns of Receptor Activator of Nuclear Factor-kB (RANK) and Src in a Series of Primary Breast Tumors (BT) and Bone Metastases (BM) in Patients (pts) with Metastatic Breast Cancer (MBC). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-16-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
BM develops in 65–70% of pts with MBC. RANK and its ligand (RANK-L) can be critical in the development and progression of BM. Src overexpression and deregulation occurs in many solid tumors but it has not been fully characterized although an association between Src activity defined by a gene expression signature and BM particularly in ER+ pts has been described. (Zhang XH et al. Cancer Cell. 2009) Our goal was to elucidate the relationship between Src and RANK expression in BT and BM in relation to estrogen-/progesterone-receptor (ER/PR)/HER2 expression and tumor histology (invasive ductal carcinoma (IDC) vs invasive lobular carcinoma (ILC)).
Methods: Immunohistochemistry (IHC) for RANK (R&D Systems clone 80707) and Src (Cell Applications Inc. Phospho Tyr-416) protein expression was performed on archived paraffin embedded BT and BM. Scoring: 0=negative, 1+=weak, 2+=intermediate, 3+=strong and the percent of positive tumor cells; RANK+ = 2–3+, > 1% of cells; Src+ = 1–3+; > 1% of cells. Associations between RANK/Src expression and tumor characteristics were assessed using the chi-square test or McNemar's test for pairs, as appropriate.
Results: From the MSKCC database, using an IRB-approved waiver of consent, we identified 54 pts with MBC who underwent surgical biopsy of a metastatic bone lesion at our center between 2005–2010, and had tissue available for further testing. 17 corresponding BT samples were identified. At the time of diagnosis, 43 (79.5%) primary tumors were ER or PR (+); 6 (11%) were HER2+; 41 (76%) were invasive ductal carcinoma. 87% of BM expressed RANK and 44% expressed Src. (Table 1) No significant correlation between RANK or Src expression in BM and ER/PR/HER2 status of BT was observed. A significant correlation between RANK expression and BT histology was observed, (p=0.0016): 93% of IDC were RANK (+), in comparison to 50% of invasive lobular carcinomas. RANK expression was not significantly different between primary tumor and metastatic bone samples (p=0.99). There was a borderline significant difference in Src expression between primary and metastatic site (p=.06).
Conclusions: In our cohort, no correlation between RANK or Src by IHC and ER/PR/HER2 was identified but RANK expression was more common in IDC than ILC. Fidelity was high for RANK between primary and metastatic lesions while Src expression may possibly vary.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-16-06.
Collapse
Affiliation(s)
- A Gucalp
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - E Comen
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - S Redana
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - L Evangelista
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - DD Giri
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - XH Zhang
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - S Patil
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - M Akram
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - L Norton
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - CA Hudis
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| | - MN Fornier
- 1Memorial Sloan-Kettering Cancer Center, New York, NY; Sloan-Kettering Institute, New York, NY; Piemontese per l'Oncologia — Institute for Cancer Research and Treatment, Candiolo, Italy; Istituto Oncologico Veneto (IOV — IRCCS), Padua, Italy
| |
Collapse
|
6
|
Redana S, Gucalp A, Ghiotto C, Vinante L, Zago G, Fornier MN, Evangelista L. Fluorodeoxiglucose (FDG)-avidity at positron emission computed tomography/computed tomography (PET/CT) during adjuvant hormone therapy (HT) in patients (pts) with breast cancer (BC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 2011; 22:2575-2581. [PMID: 21406471 DOI: 10.1093/annonc/mdr018] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND SRC plays an important role in the pathogenesis of metastatic breast cancer (MBC). In preclinical models, paclitaxel and the oral SRC inhibitor dasatinib showed greater antitumor activity than either agent. To determine the maximum tolerated dose of this combination, we conducted a phase I study. PATIENTS AND METHODS Patients with MBC; Eastern Cooperative Oncology Group performance status of zero to one; normal hepatic, renal and marrow function were eligible. Paclitaxel 80 mg/m(2) was given 3 weeks of 4. The starting dasatinib dose was 70 mg and was increased, using a standard 3 + 3 dose-escalation scheme. RESULTS Fifteen patients enrolled (median age 54 years, range 35-74). No dose-limiting toxic effects (DLTs) occurred at dasatinib doses of 70-120 mg. One DLT (grade 3 fatigue) occurred in the dasatinib 150-mg cohort, which was expanded (six patients) with no further DLTs. However, due to cumulative toxic effects (rash, fatigue, diarrhea), the recommended phase II dose is dasatinib 120 mg. Of 13 assessable patients, a partial response was seen in 4 patients (31%), including 2 patients previously treated with taxanes; all received ≥120 mg dasatinib. An additional five patients (29%) had stable disease. CONCLUSION In combination with weekly paclitaxel, the recommended phase II dose of dasatinib is 120 mg daily and preliminary activity has been seen in patients with MBC.
Collapse
Affiliation(s)
- M N Fornier
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - P G Morris
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York.
| | - A Abbruzzi
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - G D'Andrea
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - T Gilewski
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - J Bromberg
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - C Dang
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - M Dickler
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - S Modi
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - A D Seidman
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - N Sklarin
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - J Chang
- Breast Center, Baylor College of Medicine, Houston, USA
| | - L Norton
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| | - C A Hudis
- Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
| |
Collapse
|
8
|
Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang CT, Dickler MN, Norton L, Hudis C. Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1156] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Morris PG, Chang JC, Abbruzzi A, Patil S, Modi S, Seidman AD, Sklarin NT, Norton L, Hudis C, Fornier MN. Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Drullinsky P, Fornier MN, Sugarman S, D'Andrea G, Troso-Sandoval T, Seidman AD, Yuan J, Patil S, Norton L, Hudis C. Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10–11-day dosing intervals for women with early-stage breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.590] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
590 Background: CMF (C 600 mg/m2, M 40 mg/m2, F 600 mg/m2) is an option for adjuvant therapy for patients with low risk early stage breast cancer. DD regimens as predicted by mathematical models of cancer growth and treatment response are superior. We previously demonstrated the safety of DD EC (epirubicin/cyclophosphamide) followed by paclitaxel at 10–11 day (d) intervals. We investigated the feasibility of administering DD adjuvant CMF every 14 d and then every 10–11 d in a 2-stage phase II trial. Methods: An initial cohort (A) was treated q 14 d with PEG-filgrastim (Neulasta) support. A second cohort (B) was treated every 10–11 d with filgrastim/Neupogen x 5 d and then, based on feasibility, modified (cohort C) to use 7 d filgrastim. The primary end point was feasibility defined as having ANC > 1.5 x 103/uL on day 1 of planned treatment for all 8 cycles with no grade 3 or higher non-hematologic toxicity. All three cohorts were tested using a Simon's two-stage optimal design with type I and type II errors set at 10%. This design would effectively discriminate between true tolerability (as protocol-defined) rates of< 60% and> 80%. Cohort A: 38 pts with early stage breast cancer were accrued from 3/2008 though 6/2008. Cohort B: 7 pts were accrued from June 2008 through August 2008. Cohort C: Is still open with 16 pts accrued from August 2008 through December 5, 2008. Results: Median age 51: range 38 to 78. Cohort A: 29/38 pts completed 8 cycles of CMF. The regimen was considered feasible. 2 other pts completed 7 cycles and were withdrawn for depression and grade 2 transaminitis. The 7 other pts completed between 1 and 6 cycles of CMF were withdrawn as follows: 3 personal, 1 (grade 3) bone pain, 2 allergy unrelated to CMF, and 1 seizure. Cohort B: 7 pts were accrued. 6 out of 7 pts could not complete 8 cycles of chemotherapy secondary to neutropenia and 1 secondary to grade 3 ALT elevation. Cohort C: Accrual has not been completed. 16 pts are currently enrolled. Conclusions: Dose dense adjuvant CMF is feasible at 14 d intervals with PEG-filgrastim support. Adjuvant CMF every 10–11 days with filgrastim given for 5 days beginning day 2 is not feasible. Accrual is ongoing for CMF at 10–11 days with filgrastim x 7 days. Updated results will be available for Cohort C. [Table: see text]
Collapse
Affiliation(s)
- P. Drullinsky
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. N. Fornier
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Sugarman
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - G. D'Andrea
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | - A. D. Seidman
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Yuan
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Patil
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L. Norton
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C. Hudis
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
11
|
Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13:5841-6. [PMID: 17908977 DOI: 10.1158/1078-0432.ccr-07-1218] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Flavopiridol is a cyclin-dependent kinase inhibitor that enhances docetaxel-induced apoptosis in a sequence-specific manner. In vivo, docetaxel must precede flavopiridol by at least 4 h to induce this effect. We conducted a phase I trial of weekly, sequential docetaxel followed 4 h later by flavopiridol in patients with advanced solid tumors. EXPERIMENTAL DESIGN Docetaxel at a fixed dose of 35 mg/m2 was administered over 30 min, followed 4 h later by escalating doses of flavopiridol, ranging from 20 to 80 mg/m2 in successive cohorts, administered weekly over 1 h. This schedule was repeated for 3 weeks of each 4-week cycle. RESULTS Twenty-seven evaluable patients were enrolled. The combination was well tolerated, with one dose-limiting toxicity occurring at flavopiridol 70 mg/m2 (grade 3 mucositis) and one dose-limiting toxicity at 80 mg/m2 (grade 4 neutropenia). We observed 1 complete response in a patient with pancreatic carcinoma and 4 partial responses in pancreatic (1), breast (2), and ovarian (1) cancer patients. Stable disease was seen in 10 patients. Pharmacokinetic studies showed Cmax ranging from 1.49 +/- 0.69 micromol/L (flavopiridol 20 mg/m2) to 4.54 +/- 0.08 micromol/L (flavopiridol 60 mg/m2) in cycle 1. CONCLUSIONS Treatment with weekly, sequential docetaxel followed by flavopiridol is an effective and safe regimen at all flavopiridol dose levels. The pharmacokinetic data indicate that concentrations of flavopiridol that enhance the effects of docetaxel both in vitro and in vivo can be achieved. Clinical activity is encouraging, even in patients who have received a prior taxane and in patients with gemcitabine-refractory metastatic pancreatic cancer.
Collapse
Affiliation(s)
- M N Fornier
- Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
BACKGROUND Drugs that target microtubules, including paclitaxel (Taxol) and docetaxel (Taxotere), are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapies is limited by difficulties with formulation, administration, and resistance induced by P-glycoprotein. The epothilones are a novel class of antimicrotubule agents that have demonstrated antitumor activity in the setting of resistance. DESIGN This review summarizes clinical studies of epothilones in patients with metastatic breast cancer. Data were identified by searches of PubMed and the Proceedings of the American Society of Clinical Oncology annual meetings from 2000 to 2006. RESULTS The epothilones have demonstrated promising antitumor activity and manageable toxicity in phase II studies of heavily pretreated patients with metastatic breast cancer, including patients with resistance to taxanes and other cytotoxic agents. Neuropathy associated with ixabepilone appears to be schedule dependent and comparable to that observed with paclitaxel. Ixabepilone appears to be active in combination with capecitabine. CONCLUSIONS Ongoing and planned trials promise to elucidate the benefits of ixabepilone in combination with other agents including capecitabine, bevacizumab, and trastuzumab in patients with metastatic breast cancer as well as those receiving neo-adjuvant therapy.
Collapse
Affiliation(s)
- M N Fornier
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
| |
Collapse
|
13
|
Fornier MN, Martin M, Klimovsky J, Bunnell CA. Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: Final report. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10587] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10587 Background: The epothilones, a new class of antineoplastic agents, promote tumor cell death by stabilizing microtubules and inducing apoptosis. Ixabepilone was selected from over 300 epothilone analogs due to its high in vivo efficacy, good metabolic stability and low protein binding. Methods: This international, multicenter, open-label Phase II trial was designed to assess the activity of ixabepilone in patients (pts) with highly resistant MBC who had progressed following taxane treatment. Eligible pts were aged ≥18 years with MBC (progressed on or within 4 months of taxane therapy [or within 6 months if adjuvant taxane only]). Pts were excluded if they had had ≥3 prior chemotherapy regimens for MBC or had ≥Grade 2 neuropathy. Ixabepilone (40 mg/m2 q3w) was administered as a 3-hour infusion for a maximum of 18 cycles, unless there was evidence of progressive disease and/or pts met discontinuation criteria. Toxicity was evaluated continuously. Results: Of 49 pts (median age 54 years, range 30–81), 86% of pts had received ≥2 prior chemotherapy regimens. Treatment-related adverse events (TRAEs) were manageable and mostly Grade 1 or 2 (45%). Treatment-related neuropathy was mostly sensory, mild-to-moderate, cumulative and reversible. Sensory neuropathy was managed mainly with dose reductions (12 out of 49 pts had their dose reduced due to neuropathy). Treatment-limiting or severe neuropathy generally resolved or lessened in intensity within 1–2 months after therapy discontinuation. Febrile neutropenia was reported in only 2 pts, in addition, 2 pts (4%) developed treatment-related infection with neutropenia. Only six pts (12%) required growth factor support for neutropenia during their treatment. Progressive disease was the most common reason for discontinuing the study (36%), with 16% discontinuing due to TRAEs. Conclusions: Ixabepilone demonstrates an acceptable safety profile, along with promising antitumor activity, in pts with clearly defined taxane-resistant MBC. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- M. N. Fornier
- Memorial Sloan-Kettering Cancer Center, New York, NY; Hospital Universitario San Carlos, Madrid, Spain; Bristol-Myers Squibb, Wallingford, CT; Dana-Farber Cancer Institute, Boston, MA
| | - M. Martin
- Memorial Sloan-Kettering Cancer Center, New York, NY; Hospital Universitario San Carlos, Madrid, Spain; Bristol-Myers Squibb, Wallingford, CT; Dana-Farber Cancer Institute, Boston, MA
| | - J. Klimovsky
- Memorial Sloan-Kettering Cancer Center, New York, NY; Hospital Universitario San Carlos, Madrid, Spain; Bristol-Myers Squibb, Wallingford, CT; Dana-Farber Cancer Institute, Boston, MA
| | - C. A. Bunnell
- Memorial Sloan-Kettering Cancer Center, New York, NY; Hospital Universitario San Carlos, Madrid, Spain; Bristol-Myers Squibb, Wallingford, CT; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
14
|
Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005; 16:234-9. [PMID: 15668276 DOI: 10.1093/annonc/mdi059] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
PURPOSE We explored the relationship between circulating HER2 extracellular domain (ECD) and tissue HER2 status as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). We also examined its predictive value in a cohort of metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel. METHODS Eligible patients had pre- and post-treatment stored serum specimens and were treated on a previously reported phase II trial. Retrospective analysis evaluated: the association between pretreatment serum HER2 ECD and tissue HER2 status by IHC and FISH; and the association between change in serum HER2 ECD after 12 weeks of therapy and response proportion. RESULTS Stored serum samples were available for 55/95 (58%) patients. Statistically significant associations were found between HER2 status as assessed by IHC and FISH, and baseline serum HER2 ECD level. Patients whose ECD normalized after 12 weeks of therapy had a higher response proportion compared with patients with persistently high ECD levels (68% versus 15%, P=0.005). A relative decline of over 55% from baseline HER2 ECD predicted response to therapy. CONCLUSION A statistically significant association was observed between pretreatment serum HER2 ECD and tissue HER2 status as assessed by IHC and FISH. A decrease in serum HER2 ECD level was a significant predictor of response to trastuzumab-based therapy.
Collapse
Affiliation(s)
- M N Fornier
- Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
| | | | | | | | | | | | | |
Collapse
|
15
|
Fornier MN, Seidman AD, Lake D, D’Andrea G, Bromberg J, Robson M, van Poznak CH, Panageas K, Norton L, Hudis C. Increased dose-density (DD) Is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10–11 day interval with filgrastim support, for women with early breast carcinoma (BC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.616] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - D. Lake
- Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - G. D’Andrea
- Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - J. Bromberg
- Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - M. Robson
- Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | | | - K. Panageas
- Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - L. Norton
- Memorial Sloan-Kettering Cancer Ctr, New York, NY
| | - C. Hudis
- Memorial Sloan-Kettering Cancer Ctr, New York, NY
| |
Collapse
|
16
|
Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 2001; 7:3934-41. [PMID: 11751485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
PURPOSE We conducted a randomized Phase II trial to directly compare toxicity, feasibility, and delivered dose intensities of two adjuvant dose-intensive regimens containing doxorubicin, paclitaxel, and cyclophosphamide for patients with node-positive breast carcinoma. EXPERIMENTAL DESIGN Forty-two patients with resected breast carcinoma involving one or more ipsilateral axillary lymph nodes, were randomized to receive two different schedules of adjuvant chemotherapy using 14-day dosing intervals: either (a) three cycles of doxorubicin 80 mg/m(2) as i.v. bolus followed sequentially by three cycles of paclitaxel 200 mg/m(2) as a 24-h infusion and then by three cycles of cyclophosphamide 3.0 g/m(2) as a 1-h infusion (arm A); or (b) the same schedule of doxorubicin followed by three cycles of concurrent cyclophosphamide and paclitaxel at the same doses (arm B). All cycles were supported by granulocyte colony-stimulating factor administration. RESULTS Forty-one patients were assessable for toxicity and feasibility; 37 (90%) completed all planned chemotherapy. There was no treatment-related mortality; however, increased toxicity was observed on arm B compared with arm A, manifested by an increase in hospitalization for toxicity, mainly neutropenic fever, and an increased incidence of transfusion of packed RBCs transfusions for anemia. The mean delivered dose intensities for paclitaxel and cyclophosphamide were significantly greater for arm A compared with arm B (P =.01 and P =.05, respectively). There is no long-term, treatment-related toxicity, and no cases of acute myelogenous leukemia or myelodysplastic syndrome have been observed. CONCLUSIONS Dose-dense sequential single-agent chemotherapy is more feasible than doxorubicin with subsequent concurrent paclitaxel and cyclophosphamide.
Collapse
Affiliation(s)
- M N Fornier
- Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19:2587-95. [PMID: 11352950 DOI: 10.1200/jco.2001.19.10.2587] [Citation(s) in RCA: 380] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This phase II study evaluated weekly trastuzumab and paclitaxel therapy in women with HER2-normal and HER2-overexpressing metastatic breast cancer. Efficacy was correlated with immunohistochemical and fluorescent in situ hybridization (FISH) assay results. PATIENTS AND METHODS Eligible patients had bidimensionally measurable metastatic breast cancer. Up to three prior chemotherapy regimens, including prior anthracycline and taxane therapy, were allowed. Trastuzumab 4 mg/kg and paclitaxel 90 mg/m2 were administered on week 1, with trastuzumab 2 mg/kg and paclitaxel 90 mg/m2 administered on subsequent weeks. HER2 status was evaluated using four different immunohistochemical assays and FISH. RESULTS Patients received a median of 25 weekly infusions (range, one to 85 infusions). Median delivered paclitaxel dose-intensity was 82 mg/m2/wk (range, 52 to 90 mg/m2/wk). The intent-to-treat response rate for all 95 patients enrolled was 56.8% (95% confidence interval, 47% to 67%). A response rate of 61.4% (4.5% complete response, 56.8% partial response) was observed in 88 fully assessable patients. In patients with HER2-overexpressing tumors, overall response rates ranged from 67% to 81% compared with 41% to 46% in patients with HER2-normal expression (ranges reflect the different assay methods used to assess HER2 status). Differences in response rates between patients with HER2-overexpressing tumors and those with normal HER2 expression were statistically significant for all assay methods, with CB11 and TAB250 antibodies and FISH having the strongest significance. Therapy was generally well tolerated, although three patients had serious cardiac complications. CONCLUSION Weekly trastuzumab and paclitaxel therapy is active in women with metastatic breast cancer. Therapy was relatively well tolerated; however, attention to cardiac function is necessary.
Collapse
Affiliation(s)
- A D Seidman
- Breast Cancer Medicine Service, Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|